AEON Biopharma (AEON) Stock Price, News & Analysis

Company Overview

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic, rather than primarily aesthetic, applications. Its lead product candidate, ABP-450, is an investigational botulinum toxin type A complex being studied for the treatment of neurological and other medical conditions.

AEON Biopharma has advanced ABP-450 in clinical development for conditions including chronic migraine and cervical dystonia, a disorder involving involuntary neck-muscle contractions. The company has also evaluated additional potential indications for the product. ABP-450 is not an approved treatment for these conditions, and its safety and effectiveness remain subject to clinical testing and regulatory review.

The company became publicly traded in 2023 through a business combination with Priveterra Acquisition Corp. AEON Biopharma is based in the United States and operates in collaboration with research, clinical, manufacturing and regulatory partners as it seeks to develop its pipeline. Marc Forth serves as the company’s chief executive officer.

Key Stats

• Today's Range: $0.15 to $0.17
• 50-Day Range: $0.16 to $0.33
• 52-Week Range: $0.13 to $1.45
• Volume: 135,914 shs
• Average Volume: 2.68 million shs
• Market Capitalization: $7.73 million
• P/E Ratio: 0.86
• Dividend Yield: N/A
• Price Target: $1.67
• Consensus Rating: Moderate Buy

AEON Biopharma Stock Analysis - MarketRank™

AEON Biopharma scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AEON Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

AEON Biopharma has a consensus price target of $1.67, representing about 916.3% upside from its current price of $0.16.

Amount of Analyst Coverage

AEON Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AEON Biopharma is 0.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of AEON Biopharma is 0.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.41.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AEON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AEON Biopharma does not currently pay a dividend.

Dividend Growth

AEON Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for AEON Biopharma this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $241,500.00 in company stock, which represents 2.9520% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, AEON Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $241,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.70% of the stock of AEON Biopharma is held by insiders.

Percentage Held by Institutions

22.78% of the stock of AEON Biopharma is held by institutions.

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AEON
• Previous Symbol: NASDAQ:AEON
• CIK: 1837607
• Web: www.aeonbiopharma.com
• Phone: (949) 354-6499
• Fax: N/A
• Employees: 8
• Year Founded: 2012

Price Target and Rating

• Average Price Target for AEON Biopharma: $1.67
• High Price Target: $2.00
• Low Price Target: $1.20
• Potential Upside/Downside: +941.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.42)
• Trailing P/E Ratio: 0.89
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -994.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 49,883,000
• Free Float: 74,373,000
• Market Cap: $7.98 million
• Optionable: Not Optionable
• Beta: 0.68